Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioAtla, Inc. (BCAB : NSDQ)

• Company Description    BioAtla Inc. is a clinical-stage biopharmaceutical company. It engages in developing a novel class of antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla Inc. is based in SAN DIEGO. Number of Employees: 56

• Price / Volume Information    Yesterday's Closing Price: $2.30 Daily Weekly Monthly 20 Day Moving Average: 737,304 shares Shares Outstanding: 37.41 (millions) Market Capitalization: $86.05 (millions) Beta: 2.45 52 Week High: $51.83 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -42.50% -37.23% 12 Week -65.93% -63.17% Year To Date -88.28% -86.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11085 TORREYANA ROAD - SAN DIEGO,CA 92121 USA ph: 858-558-0708 fax: - investors@bioatla.com http://www.bioatla.com

• General Corporate Information    Officers Jay M. Short - Chief Executive Officer and Director Scott Smith - President and Director Richard A. Waldron - Chief Financial Officer Guy Levy - Director Lawrence Steinman - Director Peer Information BioAtla, Inc. (CORR.) BioAtla, Inc. (RSPI) BioAtla, Inc. (CGXP) BioAtla, Inc. (BGEN) BioAtla, Inc. (GTBP) BioAtla, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077B104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/12/22 Share - Related Items Shares Outstanding: 37.41 Most Recent Split Date: (:1) Beta: 2.45 Market Capitalization: $86.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -16.07% vs. Previous Quarter: -3.17% Sales Growth vs. Year Ago Period: 31.58% vs. Previous Quarter: -% ROE 03/31/22 - -48.89 12/31/21 - -46.80 09/30/21 - -43.41 ROA 03/31/22 - -40.45 12/31/21 - -39.03 09/30/21 - -36.52 Current Ratio 03/31/22 - - 12/31/21 - 12.48 09/30/21 - 6.05 Quick Ratio 03/31/22 - - 12/31/21 - 12.48 09/30/21 - 6.05 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -38,160.80 09/30/21 - -35,362.80 Book Value 03/31/22 - - 12/31/21 - 5.65 09/30/21 - 6.29 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©